Sinphar Pharmaceutical Co.,Ltd. (TPE:1734)

Sinphar Pharmaceutical Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	895.16	1,076	1,074	1,238	1,195	1,144
Short-Term Investments	99.7	95.41	-	-	43.44	43.77
Trading Asset Securities	7.04	6.96	6.66	6.66	6.66	6.66
Cash & Short-Term Investments	1,002	1,178	1,081	1,244	1,245	1,194
Cash Growth	-13.63%	8.96%	-13.11%	-0.05%	4.24%	34.77%
Accounts Receivable	691	641.9	643.47	685.19	592.97	454.61
Other Receivables	34.93	34.81	34.27	31.43	29.15	-
Receivables	725.93	676.71	677.73	716.62	622.12	454.61
Inventory	773.74	751.35	876.9	804.31	820.62	839.25
Prepaid Expenses	23.79	12.96	7.08	8.45	5.7	6.21
Other Current Assets	3.16	5.3	5.75	4.86	10.03	45.37
Total Current Assets	2,529	2,624	2,649	2,778	2,703	2,540
Property, Plant & Equipment	3,166	3,285	3,247	3,139	3,224	3,287
Long-Term Investments	50.94	54.64	22.21	24.7	20.36	27.85
Other Intangible Assets	62.93	72.16	71.82	86.98	117.3	157.53
Long-Term Deferred Tax Assets	195.14	185.37	170.86	52.11	74.88	51.86
Other Long-Term Assets	122.42	76.62	90.71	103.65	81.24	62.72
Total Assets	6,126	6,298	6,251	6,185	6,221	6,127
Accounts Payable	253.11	185.45	291.37	323.74	201.42	194.96
Short-Term Debt	348	370	400	447	587	552
Current Portion of Long-Term Debt	49.76	351.29	50.72	50.34	61.28	92.46
Current Income Taxes Payable	38.7	39.36	3.09	45.41	35.27	34.18
Current Unearned Revenue	99.53	97.42	85.65	96.56	93.64	97.8
Other Current Liabilities	354.33	379.29	373.87	482.86	555.88	358.49
Total Current Liabilities	1,143	1,423	1,205	1,446	1,534	1,330
Long-Term Debt	1,274	1,181	1,494	1,416	1,486	1,512
Pension & Post-Retirement Benefits	1.4	15.09	35.55	35.98	50.89	64.82
Long-Term Deferred Tax Liabilities	-	88.98	88.45	38.15	38.28	37.83
Other Long-Term Liabilities	134.05	44	30.37	32.68	34.12	38.1
Total Liabilities	2,553	2,752	2,853	2,968	3,144	2,983
Common Stock	1,902	1,811	1,677	1,677	1,677	1,677
Additional Paid-In Capital	924.14	924.14	924.14	929.97	963.52	941.39
Retained Earnings	617.02	648.43	634.15	444.41	210.68	244.81
Comprehensive Income & Other	-134.95	-120.76	-137.17	-121.37	-129.18	-118.99
Total Common Equity	3,308	3,263	3,098	2,930	2,722	2,744
Minority Interest	264.91	282.98	299.54	286.62	354.94	399.39
Shareholders' Equity	3,573	3,546	3,398	3,217	3,077	3,144
Total Liabilities & Equity	6,126	6,298	6,251	6,185	6,221	6,127
Total Debt	1,672	1,902	1,945	1,913	2,134	2,157
Net Cash (Debt)	-670.03	-724.46	-863.71	-668.74	-889.35	-962.71
Net Cash Per Share	-3.51	-3.80	-4.53	-3.51	-4.68	-5.06
Filing Date Shares Outstanding	190.2	190.2	190.2	190.2	190.2	190.2
Total Common Shares Outstanding	190.2	190.2	190.2	190.2	190.2	190.2
Working Capital	1,385	1,202	1,444	1,333	1,169	1,210
Book Value Per Share	17.39	17.16	16.29	15.41	14.31	14.43
Tangible Book Value	3,245	3,191	3,027	2,843	2,605	2,587
Tangible Book Value Per Share	17.06	16.78	15.91	14.95	13.70	13.60
Land	717.58	717.58	717.58	717.58	717.58	717.37
Buildings	3,165	3,195	2,978	2,927	2,882	2,866
Machinery	2,402	2,350	2,195	2,027	1,960	1,899
Construction In Progress	22.69	31.59	129.71	72.62	66.32	29.02

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.